LAKE FOREST, Ill.--(BUSINESS WIRE)-- Actient Pharmaceuticals LLC (“Actient”), a specialty pharmaceutical company, announced today that it has acquired Timm Medical Technologies, Inc. (“Timm Medical”). Timm Medical is a recognized leader in products and services for the diagnosis and treatment of urological disorders, primarily in the area of erectile dysfunction.
p> The acquisition of Timm Medical is consistent with Actient’s strategic focus in urology. Actient is now able to offer pharmaceutical, and medical device and diagnostic solutions, to the urology community.
p> “Timm Medical and the Osbon brand names are synonymous with outstanding quality and service,” said Ed Fiorentino, CEO of Actient. “We look forward to combining the companies and expanding our efforts in providing urology products and services that improve patient outcomes.”
p> “We are excited to join Actient,” commented David Talen, president of Timm Medical. “We believe that Actient will help enhance our position as a valued resource for urologists and patients.”
p> Actient was established in March 2009 in partnership with GTCR, one of the nation’s leading private equity firms. Timm Medical is Actient’s second acquisition since its founding. Actient completed its first transaction in July 2010 to license and acquire six pharmaceutical products from UCB, Inc., an international biopharmaceutical company based in Brussels, Belgium.
p> About Actient Pharmaceuticals LLC
p> Actient Pharmaceuticals is a specialty pharmaceutical company focused on therapeutics to improve patient outcomes. The company was formed to acquire companies and products with a focus on select physician specialties. For more information, please visit www.actientpharma.com.
p> About GTCR
p> Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered the “Leaders Strategy” – finding and partnering with world-class leaders as the critical first step in identifying, acquiring and building market-leading companies through acquisitions and organic growth. Since its inception, GTCR has invested more than $8.0 billion in over 200 companies. For more information, please visit www.gtcr.com.
p> The Harbinger Group Eileen Rochford, 312-953-3305
p> Source: GTCR
p> Copyright Business Wire 2011
